Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Core Viewpoint - Ocugen, Inc. has successfully closed an underwritten registered direct offering of 15 million shares at $1.50 per share, resulting in net proceeds of $20.85 million, aimed at supporting its operations and extending its cash runway into Q4 2026 [1][2]. Group 1: Offering Details - The offering consisted of 15,000,000 shares priced at $1.50 each, leading to net proceeds of $20.85 million after expenses [1]. - The financing was led by RTW Investments, with participation from both new and existing investors [1]. - Oppenheimer & Co. served as the sole book-running manager for the offering [2]. Group 2: Use of Proceeds - The net proceeds will be allocated for general corporate purposes, capital expenditures, working capital, and administrative expenses [2]. - The funding is expected to extend the company's cash runway into the fourth quarter of 2026 [2]. Group 3: Company Overview - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, utilizing a modifier gene therapy platform to address complex diseases caused by multiple gene network imbalances [5]. - The company is developing programs for inherited retinal diseases and blindness conditions affecting millions globally, including retinitis pigmentosa, Stargardt disease, and geographic atrophy [5].